Inactive

January 28, 2021 - Amendment 1 to FDABAA-21-00123 has been posted to provide updated contact details for the ongoing administration of the BAA. White Papers must still be submitted to the same general... January 28, 2021 - Amendment 1 to FDABAA-21-00123 has been posted to provide updated contact details for the ongoing administration of the BAA. White Papers must still be submitted to the same general FDABAA inbox as specified in the announcement, and all other submission requirements remain unchanged and unaffected by this amendment. All other terms, conditions and provisions of FDABAA-21-00123 remain unchanged. ********************************************************* In accordance with FAR 6.102(d)(2) and 35.016, the US Food and Drug Administration (FDA) solicits for the acquisition of basic and applied research and development proposals to support regulatory science and innovation through this Broad Agency Announcement (BAA). Research and development activities acquired under this BAA are intended to advance scientific knowledge in specific research areas of interest defined within the BAA which serve the FDA in accomplishing its mission to protect and promote the health of our nation. Proposals submitted under this announcement are not limited solely to the PSC code "AJ11" specified in this announcement. *This announcement is a renewal of the prior-year FY20 announcement (FDABAA-20-00123) and will remain open until further notice. This announcement is renewed on an annual basis.